H.C. Wainwright analyst Andres Maldonado initiated coverage of ImmunityBio (IBRX) with a Buy rating and $8 price target ImmunityBio is a ...

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for Anktiva ...

ImmunityBio (IBRX) announced the U.S. Food and Drug Administration has granted Regenerative Medicine Advanced Therapy designation for ANKTIVA ...

Culver City, California Saturday, March 1, 2025, 17:00 Hrs [IST] ...

Global submission of marketing authorization applications (MAAs) for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without papillary tumors for ANKTIVA in combination with ...

ImmunityBio’s revenue growth was driven by sales of its ANKTIVA therapy following FDA approval in April 2024. The company reported net product revenue of $7.2 million for Q4, representing a 21% ...

Cytokine fusion proteins, such as ANKTIVA, represent a novel class of biologics that improve immune responses by enhancing the therapeutic potential of cytokines and promoting lymphocyte ...

The stock market kicked off the trading week in a bloodbath, erasing last week’s gains, with all major indices posting heavy ...

ImmunityBio’s revenue growth was driven by sales of its ANKTIVA therapy following FDA approval in April 2024. The company reported net product revenue of $7.2 million for Q4, representing a 21% ...

ImmunityBio shares advanced 17% to $3.34 after the company said the Food and Drug Administration awarded a regenerative medicine advanced therapy designation for Anktiva and CAR-NK for the reversal of ...

Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and ...